Inhibition of neurotransmitter receptor binding by ergot derivatives

Robert E. Hruska, Ellen K. Silbergeld

Research output: Contribution to journalReview articlepeer-review


Bromocriptine, lergotrile, lisuride, metergoline, and the Sandoz ergot derivatives 25–397, 29–712, and 29–717 have been tested for their ability to inhibit the synaptic receptor binding of spiroperidol, 5‐hydroxytryptamine (5‐HT), d‐lysergic acid diethylamide (LSD), quinuclidinyl benzilate (QNB), WB.4101, and γ‐aminobutyric acid (GABA). Only GABA binding was not affected, and QNB binding was decreased only by lergotrile and metergoline at high concentrations. The most potent inhibitors of the other ligands were bromocriptine and lisuride for spiroperidol (1–2 nM), metergoline for 5‐HT (29 nM), lisuride for LSD (15 nM), and lergotrile for WB.4101 (17 nM). The direct receptor effects of the ergot derivatives in vitro may contribute to understanding their in vivo effects on behavior and in predicting their therapeutic potential in neurological and neuroendocrine disorders.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalJournal of neuroscience research
Issue number1
StatePublished - 1981
Externally publishedYes


  • bromocriptine
  • lergotrile
  • lisuride
  • metergoline
  • receptors

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Inhibition of neurotransmitter receptor binding by ergot derivatives'. Together they form a unique fingerprint.

Cite this